EP
JBIO

Eversept Partners’s Jade Biosciences JBIO Stock Holding History

Eversept Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,861
Closed -$1.01M – 68
2024
Q3 		$1.01M Buy
+13,861
New +$894K 0.07% 64
2024
Q2 		– Sell
-1,547
Closed -$1.6M – 75
2024
Q1 		$1.6M Buy
1,547
+112
+8% +$85.5K 0.11% 64
2023
Q4 		$1.14M Hold
1,435
– – 0.1% 54
2023
Q3 		$682K Hold
1,435
– – 0.06% 67
2023
Q2 		$862K Hold
1,435
– – 0.07% 65
2023
Q1 		$1.01M Sell
1,435
-1,172
-45% -$972K 0.07% 58
2022
Q4 		$2.67M Buy
+2,607
New +$1.89M 0.23% 44

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

Eversept Partners's JBIO Position: Q4 2024 in Review

Eversept Partners sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 13,861 shares — an estimated $1.01M sold.

Eversept Partners first reported a position in JBIO in Q4 2022 and held it in 7 quarters. The position peaked at $2.67M in Q4 2022. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • Eversept Partners reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • Eversept Partners sold 13,861 Jade Biosciences shares in Q4 2024, an estimated $1.01M.
  • Eversept Partners first reported a position in Jade Biosciences in Q4 2022 and held it in 7 quarters.
  • Eversept Partners's Jade Biosciences position peaked at $2.67M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.